학술논문
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors
CORONAV I RUS
CORONAV I RUS
Document Type
Academic Journal
Author
Uyoga, Sophie; Adetifa, Ifedayo M. O.; Karanja, Henry K.; Nyagwange, James; Tuju, James; Wanjiku, Perpetual; Aman, Rashid; Mwangangi, Mercy; Amoth, Patrick; Kasera, Kadondi; Ng'ang'a, Wangari; Rombo, Charles; Yegon, Christine; Kithi, Khamisi; Odhiambo, Elizabeth; Rotich, Thomas; Orgut, Irene; Kihara, Sammy; Otiende, Mark; Bottomley, Christian; Mupe, Zonia N.; Kagucia, Eunice W.; Gallagher, Katherine E.; Etyang, Anthony; Voller, Shirine; Gitonga, John N.; Mugo, Daisy; Agoti, Charles N.; Otieno, Edward; Ndwiga, Leonard; Lambe, Teresa; Wright, Daniel; Barasa, Edwine; Tsofa, Benjamin; Bejon, Philip; Ochola-Oyier, Lynette I.; Agweyu, Ambrose; Scott, J. Anthony G.; Warimwe, George M.
Source
Science. Jan 1, 2021, Vol. 371 Issue 6524, p79, 4 p.
Subject
Language
English
ISSN
0036-8075
Abstract
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Africa is poorly described. The first case of SARS-CoV-2 in Kenya was reported on 12 March 2020, and an overwhelming number of cases and deaths were expected, but by 31 July 2020, there were only 20,636 cases and 341 deaths. However, the extent of SARS-CoV-2 exposure in the community remains unknown. We determined the prevalence of anti-SARS-CoV-2 immunoglobulin G among blood donors in Kenya in April-June 2020. Crude seroprevalence was 5.6% (174 of 3098). Population-weighted, test-performance-adjusted national seroprevalence was 4.3% (95% confidence interval, 2.9 to 5.8%) and was highest in urban counties Mombasa (8.0%), Nairobi (7.3%), and Kisumu (5.5%). SARS-CoV-2 exposure is more extensive than indicated by case-based surveillance, and these results will help guide the pandemic response in Kenya and across Africa.